- Biden Administration to Back Lifting of COVID Vaccine Patents
- Health Highlights: May 6, 2021
- When Black Americans Encounter Police Violence, High Anxiety Often Follows
- Real-World Studies Show Pfizer Vaccine Shields Against COVID Variants
- Drug Saxenda Aids Weight Loss — But You Should Exercise, Too
- Israel Study: Pfizer Vaccine Gives 95% Protection Against Illness, Hospitalization & Death
- Better Access to Birth Control Boosts School Graduation Rates
- What Was Antarctic Explorer Ernest Shackleton’s Mystery Illness?
- Many Consumers Misunderstand Those ‘Best Before’ Food Labels
- U.S. COVID Outlook Shows Big Improvement by July
Enzyme Replacement May Help in Fabry Disease
WEDNESDAY, Dec. 2New research suggests that enzyme replacement therapy can make a major difference in the lives of people with Fabry disease, a rare illness that affects the kidneys, heart and brain.
The progressive disease, linked to the lack of an enzyme that helps metabolic pathways function in the body, can be fatal because it boosts the risk for a stroke, heart attack and kidney disease.
A study published Dec. 1 in The Lancet analyzed a treatment that replaced an enzyme called agalsidase alfa.
The researchers found that the treatment reduced signs of heart disease in people who had oversized hearts. It also appeared to improve kidney function, lower pain levels and improve scores on quality-of-life surveys.
“Enzyme-replacement therapy has only been available typically since 2001, and, thus, duration of exposure might be too short to assess whether this strategy prolongs life,” the researchers wrote in an accompanying commentary. Whether the treatment, which they described as costly, helps people live longer needs confirmation, they noted.
More information
The U.S. National Institute of Neurological Disorders and Stroke has more on Fabry disease.
Source: HealthDay
